MarketingMedicalPolicy,Access,Value, andEvidenceConsultingData,Technology,and Media
murmuration of birds
Previous
Next

thought leadership

Digital therapeutics as a combination therapy: Maximizing asset value and therapeutic outcomes

Kirsten Rennie, Senior Associate Consultant & Hassan Choudhury, Early-Stage Strategy Lead | 9/20/2023

Digital therapeutics can increase the value of medicinal assets, driving differentiation and improving outcomes for patients. But are manufacturers prepared to capitalize on this significant untapped opportunity before the tech giants dominate?

By 2026, the number of people using digital therapeutics is estimated to increase by 381%, reaching a market size of $28 billion. This makes digital therapeutics the fastest-growing field in digital health.

Digital therapeutics are evidence-based therapeutic interventions, designed to prevent, manage, or treat a variety of medical conditions, ranging from chronic diseases and neurological disorders to tackling challenges such as medication adherence.

The benefits are far-reaching, from optimizing patient outcomes to reducing the economic burden on healthcare systems. However, the real value lies when digital therapeutics are combined with a medicinal asset. This powerful combination uncovers a wealth of untapped opportunities for biopharmaceutical companies to maximize the value of medicinal assets, driving differentiation and increasing access to safe and effective therapies.

To capitalize on this opportunity, the digital therapeutic must support an asset to fulfill an unmet need. However, as tech giants shape this arena and more needs are catered to, it will become difficult to develop digital platforms that increase value for all stakeholders. As a result, early market entry is fundamental.

In this whitepaper, our consultants explore the market landscape and provide strategic recommendations for manufacturers to leverage the power of digital therapeutics to enhance the value of products and portfolios including:

  • Digital therapeutics market growth
  • Key therapy areas and applications
  • Detailed benefits for stakeholders and advice on overcoming adoption hurdles
  • Strategic recommendations for developing a digital therapeutics commercialization strategy that crystalizes the value of an asset

In October 2023, Fishawack Health rebranded to Avalere Health, unifying our organization under a single team and vision to faster connect patients with life-enhancing therapies.

How we use cookies

Cookies are files saved on your phone, tablet or computer when you visit a website.

We use cookies to store information about how you use the Fishawack Health website, such as the pages you visit.

For more information, check the cookie statement

32E8261E-A569-4B66-ACC6-3CB772DDEDEE

Cookie settings

We use 4 types of cookies. You can choose which cookies you're happy for us to use.

Cookies that measure website use.

We use Google Analytics to measure how you use the website so we can improve it based on user needs. We do not allow Google to use or share the data about how you use this site.

  • how you got to the site
  • the pages you visit on fishawack.com, and how long you spend on each page
  • what you click on while you're visiting the site

Cookies that help with our communications and marketing

These cookies may be set by third party websites and do things like measure how you view Vimeo videos that are on Fishawack.com.

Cookies that remember your settings

These cookies do things like remember your preferences and the choices you make, to personalize your experience of using the site.

Strictly necessary cookies

These essential cookies do things like remember your progress through a form (eg. Registering for new content alerts).

These cookies always need to be on.